Fig. 3

The expression of Tyro3TK on CD14⁺CD16⁻ monocytes is increased in RA. a Gating strategy for identifying the expression of Tyro3TK on CD14⁺CD16⁺ and CD14⁺CD16⁻ monocytes. Accordingly, the expression of Tyro3TK on CD14⁺CD16⁺ and CD14⁺CD16⁻ monocytes in HC (n = 40) (b), OA (n = 28) (c), and RA patients (n = 40, **P = 0.008) (d) were analyzed and presented as the mean fluorescence intensity (MFI). e The expression of Tyro3TK on CD14⁺CD16⁺ monocytes were compared between HC, OA, and RA patients. f The expression of Tyro3TK on CD14⁺CD16⁻ monocytes were compared between HC, OA, and RA patients (**P = 0.004, ***P < 0.001). g Flow cytometry-sorted CD14⁺CD16⁻ monocytes from RA (n = 4) and HC (n = 4) were set to detect the mRNA expression of Tyro3TK by qPCR (*P = 0.029). *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant (Mann-Whitney U test, b, d, and g; Student’s t test, c; Kruskal-Wallis test followed by Dunn’s post-test for multiple comparisons, e–f)